Key facts
- This page summarizes Janet Huffman's Form 4 filing for TRxADE HEALTH, INC (SCNX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 24 Feb 2023, 15:45.
Janet Huffman - 13 Dec 2022 Form 4 Insider Report for TRxADE HEALTH, INC (SCNX)
- Reporting relationship
- CFO, PAO, PFO
- Issuer ticker
- SCNX
- Reported as of
- 13 Dec 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Feb 2023, 15:45:23 UTC
- Prior SEC filing
- 16 Sep 2022
- Next SEC filing
- 08 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Janet Huffman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Janet Huffman filed Form 4 for TRxADE HEALTH, INC (SCNX) on 24 Feb 2023.
Change
- Previous filing in this sequence was filed on 16 Sep 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MEDS
transaction
Common stock
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- +232%
- Price
- $0.000000
- Shares after
- 71,551
- Date
- 13 Dec 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on December 31, 2022, March 31, 2023, June 30, 2023 and September 30, 2023, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).
Footnote F2
Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as Chief Financial Officer.